S-1/A: Nexalin Tech Files for Stock Resale Amid Financial Woes

Nexalin Technology, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 5,752,823 shares of common stock by selling stockholders, while the company grapples with significant financial challenges and Nasdaq listing requirements.

Summary

• Nexalin Technology, Inc. is filing an amended S-1 registration statement to permit the resale of up to 5,752,823 shares of its common stock by selling stockholders, primarily Alumni Capital, LP.
• The company is facing significant financial difficulties, including substantial accumulated losses and a going concern warning from its auditors.
• Nexalin has been working to regain compliance with Nasdaq listing requirements, specifically the minimum bid price and minimum stockholders equity, with a deadline of January 4, 2027, for the latter.
• The company is developing neurostimulation devices for mental health conditions, with Gen-2 SYNC and Gen-3 HALO devices in development and clinical trials.
• Recent developments include a Latin America Distribution Agreement, a PONM acquisition, and the establishment of a committed equity facility with Alumni Capital, LP.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant ongoing losses, substantial doubt about the company's ability to continue as a going concern, and the precarious Nasdaq listing status, despite efforts to regain compliance.

Positives

• The company has regained compliance with the minimum bid price requirement for Nasdaq listing as of September 30, 2026.
• A pivotal clinical trial for the HALO Clarity device for insomnia has been initiated, with patient recruitment underway.
• Positive results from a clinical study evaluating the Gen-2 SYNC device for pain reduction in veteran patients with Mild Traumatic Brain Injury (mTBI) were reported.
• The company acquired software and intellectual property for its Nexalin NeuroCare digital health platform.
• A Distribution Agreement for the Nexalin Sync device was signed for Latin America, effective September 22, 2026.

Negatives

• The company has incurred significant net losses, totaling approximately $8.22 million in 2025 and $4.34 million for the first six months of 2026.
• An accumulated deficit of approximately $97.2 million as of June 30, 2026, raises substantial doubt about the company's ability to continue as a going concern.
• The company's stockholders' equity of $1.52 million as of June 30, 2026, is below the $2.5 million minimum required by Nasdaq for continued listing.
• Material weaknesses in internal control over financial reporting have been identified, including insufficient segregation of duties and IT controls.
• The company has a limited operating history and is in the early stages of product development, with no guarantee of future profitability.

Risks

• The company may never achieve or maintain profitability and expects to incur significant expenses and operating losses over the next several years.
• There is substantial doubt about the company's ability to continue as a going concern, and its ability to do so is dependent on executing its business plan and obtaining additional financing.
• Failure to demonstrate compliance with the minimum stockholders equity requirement by January 4, 2027, could lead to delisting from The Nasdaq Capital Market.
• The company may require additional funding to meet its financial needs, and if unable to raise capital, it could be forced to delay or cease product development or commercialization efforts.
• The company has identified material weaknesses in its internal controls, which could impair its ability to produce accurate financial statements.
• The medical industry in China is highly regulated and subject to change, which could affect the approval and commercialization of products.
• Future equity offerings could dilute existing stockholders' ownership, and the terms of new securities may include superior preferences.
• The company's common stock could be delisted from Nasdaq, leading to limited market quotations, reduced liquidity, and a decreased ability to raise capital.

Future Outlook

The company anticipates continued significant expenses and operating losses over the next several years as it advances product development, seeks regulatory approvals, and builds commercialization capabilities. Its ability to continue as a going concern is dependent on executing its business plan and obtaining additional financing. The company aims to obtain FDA marketing authorization for its HALO and SYNC devices and expand commercialization in the U.S. and other territories.

Management Comments

• Management concluded that disclosure controls and procedures and internal control over financial reporting were not effective as of June 30, 2026, due to material weaknesses.
• Management intends to remediate material weaknesses by implementing enhancements and controls within accounting systems and hiring qualified personnel, subject to budget limitations.
• Management has concluded that its plans do not alleviate the substantial doubt about the company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Nexalin operates in the highly competitive and regulated medical device sector, specifically focusing on neurostimulation for mental health. The company's reliance on FDA approvals and the evolving regulatory landscape in both the U.S. and China present significant challenges and opportunities.

Comparison to Industry Standards

• The company's net loss of $8.22 million in 2025 and $4.34 million in the first half of 2026, coupled with an accumulated deficit of $97.2 million, indicates a significant cash burn rate, which is common for early-stage medical device companies but requires substantial ongoing funding.
• The need for FDA approval for its Gen-2 SYNC and Gen-3 HALO devices aligns with industry standards for medical device commercialization, but the delays and reclassification issues faced by Nexalin highlight the complexities and risks inherent in this process.
• The company's efforts to secure financing through an at-the-market offering and a committed equity facility are standard practices for companies in this stage, but the terms and potential dilution are critical factors for investors to consider.
• The Nasdaq delisting concerns, particularly regarding minimum stockholders' equity, are a critical hurdle. Many small-cap companies face similar challenges in meeting exchange listing requirements, often requiring reverse stock splits or significant capital raises.

Corporate Governance

Related Party Transactions

• The company has a joint venture (48% owned by Nexalin) with Wider Come Limited (52% owned by Wider), a related party, for activities in China.
• Revenue from sales to Wider in 2025 was $49,671 and in 2024 was $4,890.
• The company acquired PONM, Inc. from GreenLight Ventures LLC (GLV) and entered into a Collaboration Agreement with GLV, with consideration paid in company stock.

Stakeholder Impact

• Existing shareholders face potential dilution from future equity offerings and sales under the AMPA.
• Shareholders are at risk of losing investment if the company fails to achieve profitability or maintain Nasdaq listing.
• Creditors may be concerned about the company's going concern status and ability to repay debt.
• Employees may face uncertainty regarding job security due to the company's financial condition and potential delisting.

Next Steps

• Demonstrate compliance with the minimum stockholders equity requirement of $2,500,000 by January 4, 2027, to maintain Nasdaq listing.
• Continue patient recruitment and enrollment for the Gen-3 HALO device clinical trial for insomnia.
• Pursue FDA marketing authorization for HALO and SYNC devices.
• Potentially utilize the Any Market Purchase Agreement (AMPA) to raise capital.
• Wind down the wholly owned subsidiary, Beijing Nexalin Neurotech Co., Ltd. (WOFE).

Key Dates

Recommendation

The company is in a highly speculative phase with significant financial challenges, including ongoing losses and a going concern warning. While there are promising developments in product trials and potential for future FDA approvals, the immediate risks related to Nasdaq delisting, financing needs, and the long path to profitability warrant a cautious approach. A 'hold' recommendation reflects the potential upside if regulatory and financial hurdles are overcome, balanced against the substantial downside risks.

Keywords

medical device, neurostimulation, mental health, anxiety, insomnia, depression, FDA, registration statement